Advance with

When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.

Our

COTA leverages our proprietary abstraction technology and oncology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation.

We form flexible and collaborative partnerships with life science companies to shape the future of real-world evidence.

Our

#6846 - COTA Healthcare homepage redesign - inform

Inform

Market of current oncologics and decisions to drive future therapeutic areas.

#6846 - COTA Healthcare homepage redesign - accelerate

Accelerate

Drug development and build real-world comparator arms.

#6846 - COTA Healthcare homepage redesign - inspire

Inspire

New ways of thinking about how trials are designed.

Our

Data Source

Abstraction

Flexibility

Curation Depth

Latest

COTA Extends Research Collaboration Agreement With The U.S. Food and Drug Administration

COTA has extended its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) for an additional three years. This renewed RCA will expand on the objective to explore the applications of real-world data in oncology.
friends of cancer research logo

New Findings Released – RWE Pilot 2.0 Project

Friends of Cancer Research leads collaborative effort including COTA and nine other organizations to advance the collective understanding in applications of real-world data. New findings reveal further insights in non-small cell lung cancer (NSCLC) with a particular focus on novel treatment strategies.

Getting

COTA captures clinical data from EHR from multiple provider sources across the United States, including both academic and community cancer programs. We also use non-EHR sources such as publicly available and proprietary databases, to generate a rich and precise dataset for use by life sciences companies.

COTA collects all clinically-relevant data points to create a rich, in-depth longitudinal cancer patient journey from our healthcare providers’ EHR. Data elements captured may vary per cancer type, but generally, our data contains (but is not limited to) detailed demographic, pathologic, genomic, treatment, and outcomes data.

Life sciences companies have used our data to support HEOR, commercial assessments, and clinical development, including supplementing clinical trial data with RWD in the form of external comparator controls. We are open to discussing any other opportunities, as well as your data needs and how COTA can generate value for your organization.

We work with life science companies interested in using oncology RWD to accelerate drug development and bring clarity to cancer. We work with the top global pharmaceutical companies, though our partners range from multinational pharma to emerging biotechs.

Our collaborative and flexible approach enables us to succeed with emerging biopharma partners. We work alongside EBPs to provide analytical, medical, and strategic support to validate use of COTA data towards EBP goals.

Interested in learning more about how we can transform cancer care together?